As we all face a cost of living crisis with the poor and the young hardest hit, Andrew Bell insists that Opera needs more subsidy. Is this a more tenable position than his defence of the Red Rock Resources (RRR) share price? I start with that then onto the two big losers from yesterday's surprising mid terms in the USA. Then onto Kefi Gold & Copper (KEFI), Ithaca Energy (ITH), MGC Pharmaceiticals (MXC) - which looks like a possible zero - and Dignity (DTY).

I have warned you for a long time, notably with this dossier HERE, that Standard Listed MGC Pharmaceuticals (MXC) is a dog with fleas drowning in a sea of red flags. Today’s quarterlies, coming after six ramptastic announcements so far this month are piss poor and written with intent to deceive.

I start on the sacking of the Chancellor. The Tories are - deservedly - electoral toast. Not that Labour will be any less incompetent. Then it is on to MGC Pharmaceuticals (MXC) and to Premier Miton (PMI)

Following the publication of my red flag dossier earlier this year, anyone owning shares in MGC Pharmaceuticals (MXC) was fully warned of the need to lube up. I hope they did. The shares were 2.25p back on 11 January when I warned you that this was a £70 million dog from the scholars and gentleman at Turner Pope.  They are now just 0.825p but after another red flag admission today they are still a monstrous sell.

The numbers for the year to June 30 came out last Thursday. Forgive my delayed response but suffice to say that MGC (MXC) engaged in industrial scale turd polishing.

The whisteblower tells truly salacious stories - I shall speak to them at length, later. I discuss FinnCap (FCAP), the fraud Supply@ME Capital (SYME), IQE (IQE), the chocolate teapots at the FCA, and MGC Pharmaceuticals (MXC). Gotcha!

Below, you can see two photos of the Greek Hovel, where I have now arrived. Gosh, it is wonderful here. I describe my trip, starting in Wrexham at 12:00 on Monday, and ending at 3 PM GMT today. There was a great deal of anxiety involved, including the most stressful half an hour i can remember at a toll booth near Aix. Then, there were the pretty young lesbians snuggled up on the sofa next to us, as we took the ferry from Bari. Then, it is onto IQE (IQE), MGC Pharmaceuticals (MXC) and Optibiotix (OPTI). Now for a swim; normal service resumes tomorrow.

I share a few thoughts with you - truths one cannot say in public - about the game last night. Notwithstanding that, I enjoyed the match, and the Northern Ireland girls held their heads up. Then, I discuss Canadian Overseas Petroleum (COPL), explaining my Christmas sub-10p target - the shares really will halve from here. I look at Shield Therapeutics (STX), MGC Pharmaceuticals (MXC), and Science in Sport (SIS) which, at every level, looks a stinker - even after today's 22% fall, the shares are grotesquely overvalued. I explain why. Finally, I describe why Malcolm should have learned from IQE (IQE) before continuing to tip Zoo Digital (ZOO) - as he has again done, today.

MGC Pharmaceuticals (MXC) is drowning in red flags, as I exposed HERE. Moreover, it is almost out of cash, as I noted HERE. Hence, it has today announced the seventh ramptastic RNS since May 27. Seven in six weeks is pretty good going, but the recent share slump - 2.25p six months ago, to 1.1p on May 27, to just 0.975p today - is even more telling.

He might come home with a raft of certificates for "Welsh speaker of the week", or other such academic achievements, but Joshua is no great sportsman. Yet this afternoon, it is the school sports day, and the whole family is off to watch him. Discussing what lies ahead with him as we walked to school this morning, filled me with pride. In the main podcast, I look at Forward Partners (FWD) - another disastrous 2021 IPO; Petropavlovsk (POG), as it races to zero; Genflow Biosciences (GENF); MGC Pharmaceuticals (MXC) - placing ahoy; and Verditek (VDTK), where things could get very messy within days. Ref MXC, I discuss two historic examples of biotech's presenting data - on AIDS "cures", and its spoof ramp last week.

The last quarterly report from MGC Pharmaceuticals (MXC) showed that, as of 31 March, it had cash of just A$ 4.004 million - having spunked just over A$ 3.9 million in that quarter. You can do the maths…

Happy St David’s Day and happy pancake day. I start with the spread betters and Russian stocks notably Petropavlovsk (POG), Eurasia (EUA) and Polymetal (POLY). Then I look in detail at MGC Pharmaceiticals (MXC), how it legged over investors in November and is a massive short even now before turning to Vast Resources (VAST), Advanced Oncotherapy (AVO), Cellular Goods (CBX),Novacyt (NCYT) and Avacta (AVCT) my big sector short which has seen its shares collapse to 46p but could easily halve again within weeks.

Hell: who cares about the rules anyway? This is London, cesspit central, and as for the rationale given for wholesale share dumping it is obvious tosh too.  The PDMR in question is Nadya Lisovoder, the chief research office at MGC (MXC) who is a very naughty, naughty girl and needs her bottom spanking

Pot play MGC Pharmaceuticals (MXC) joined the Standard List on 9 February 2021 and has already issued more RNS releases than most companies do in a lifetime. But that is not the only red flag relating to this dual listed ASX entity now being touted by certain chatroom trolls as the next big thing. MGC is drowning in red flags and its valuation is absurd.